IL136345A0 - Method to enhance an immune responce of nucleic acid vaccination - Google Patents

Method to enhance an immune responce of nucleic acid vaccination

Info

Publication number: IL136345A0
Authority: IL; Israel
Prior art keywords: responce; immune; enhance; nucleic acid; acid vaccination
Prior art date: 1997-12-16

Application number

IL13634598A

Other languages

English (en)

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-16

Filing date

1998-12-11

Publication date

2001-05-20

1998-12-11 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

2001-05-20 Publication of IL136345A0 publication Critical patent/IL136345A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

IL13634598A 1997-12-16 1998-12-11 Method to enhance an immune responce of nucleic acid vaccination IL136345A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9726555.7A GB9726555D0 (en)	1997-12-16	1997-12-16	Vaccine
PCT/EP1998/008152 WO1999030733A1 (en)	1997-12-16	1998-12-11	Method to enhance an immune response of nucleic acid vaccination

Publications (1)

Publication Number	Publication Date
IL136345A0 true IL136345A0 (en)	2001-05-20

Family

ID=10823687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13634598A IL136345A0 (en)	1997-12-16	1998-12-11	Method to enhance an immune responce of nucleic acid vaccination

Country Status (18)

Country	Link
US (2)	US6500432B1 (zh)
EP (1)	EP1037662A1 (zh)
JP (1)	JP2002508333A (zh)
KR (1)	KR20010024731A (zh)
CN (1)	CN1284883A (zh)
AR (1)	AR017866A1 (zh)
AU (1)	AU740729B2 (zh)
BR (1)	BR9814285A (zh)
CA (1)	CA2313005A1 (zh)
GB (1)	GB9726555D0 (zh)
HU (1)	HUP0100197A3 (zh)
IL (1)	IL136345A0 (zh)
NO (1)	NO20003087L (zh)
NZ (1)	NZ504936A (zh)
PL (1)	PL341212A1 (zh)
TR (1)	TR200001737T2 (zh)
WO (1)	WO1999030733A1 (zh)
ZA (1)	ZA9811501B (zh)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1200115T3 (da) *	1999-07-22	2006-01-16	Aventis Pharma Inc	Erythropoietinformuleringer af multidosistypen
WO2001012223A2 (en)	1999-08-19	2001-02-22	Dynavax Technologies Corporation	Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
EP1964573B1 (en) *	1999-10-22	2014-11-26	Aventis Pasteur Limited	Method of inducing and/or enhancing an immune response to tumor antigens
FR2804026B1 (fr) *	2000-01-21	2004-06-11	Merial Sas	Vaccination contre l'herpesvirose canine et vaccins
US7713942B2 (en) *	2001-04-04	2010-05-11	Nordic Vaccine Technology A/S	Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
CU23244A1 (es) *	2001-07-16	2007-10-17	Ct Ingenieria Genetica Biotech	Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
WO2003053464A1 (en) *	2001-12-20	2003-07-03	Aventis Pasteur Limited	Immunogenic compositions comprising an antigen and a purified m protein from respiratory syncytial virus
ATE538808T1 (de) *	2002-03-28	2012-01-15	Brenntag Biosector As	Kombinierte dns/protein impfstoffzusammensetzungen
ATE348633T1 (de) *	2002-07-05	2007-01-15	Lipoxen Technologies Ltd	Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
US20090110702A1 (en) *	2002-07-12	2009-04-30	The Johns Hopkins University	Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en)	2002-07-12	2015-12-01	The Johns Hopkins University	Mesothelin vaccines and model systems
AU2003259109A1 (en) *	2002-07-12	2004-02-02	The Johns Hopkins University	Mesothelin vaccines and model systems
AU2003292136A1 (en) *	2002-11-26	2004-06-18	Eurocine Ab	Vaccines against viruses with cationic substances as adjuvants
US8080642B2 (en) *	2003-05-16	2011-12-20	Vical Incorporated	Severe acute respiratory syndrome DNA compositions and methods of use
US20060024670A1 (en) *	2004-05-18	2006-02-02	Luke Catherine J	Influenza virus vaccine composition and methods of use
TW200613554A (en) *	2004-06-17	2006-05-01	Wyeth Corp	Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
WO2006078979A2 (en)	2005-01-20	2006-07-27	Nature Technology Corp.	Vectors and methods for genetic immunization
WO2006110344A1 (en) *	2005-04-07	2006-10-19	Wyeth	Novel methods for inducing an immune response against human immunodefiency virus
FR2893254B1 (fr)	2005-11-14	2007-12-21	Biomerieux Sa	Composition comprenant un vecteur synthetique colloidal bioresorbable et un vecteur viral et son utilisation prophylactique, therapeutique et diagnostique.
US8097419B2 (en)	2006-09-12	2012-01-17	Longhorn Vaccines & Diagnostics Llc	Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en)	2006-09-12	2014-02-18	Longhorn Vaccines & Diagnostics, Llc	Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en)	2006-09-12	2016-11-01	Longhorn Vaccines And Diagnostics, Llc	Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US9598462B2 (en)	2012-01-26	2017-03-21	Longhorn Vaccines And Diagnostics, Llc	Composite antigenic sequences and vaccines
US8080645B2 (en)	2007-10-01	2011-12-20	Longhorn Vaccines & Diagnostics Llc	Biological specimen collection/transport compositions and methods
EP2333091B1 (en)	2007-05-29	2017-06-21	Nature Technology Corporation	Vectors and methods for genetic immunization
US11041215B2 (en)	2007-08-24	2021-06-22	Longhorn Vaccines And Diagnostics, Llc	PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en)	2007-10-01	2017-06-20	Longhorn Vaccines And Diagnostics, Llc	Biological specimen collection and transport system
EP3058954B1 (en)	2007-08-27	2017-03-01	Longhorn Vaccines and Diagnostics, LLC	Immunogenic compositions and methods
US10004799B2 (en)	2007-08-27	2018-06-26	Longhorn Vaccines And Diagnostics, Llc	Composite antigenic sequences and vaccines
US11041216B2 (en)	2007-10-01	2021-06-22	Longhorn Vaccines And Diagnostics, Llc	Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP2535428B1 (en)	2007-10-01	2015-09-09	Longhorn Vaccines and Diagnostics, LLC	Biological specimen collection and transport system and methods of use
US9650639B2 (en)	2008-05-19	2017-05-16	Advaxis, Inc.	Dual delivery system for heterologous antigens
EP2853269B1 (en)	2008-05-19	2019-05-01	Advaxis, Inc.	Dual delivery system for heterologous antigens comprising a recombinant Listeria strain attenuated by mutation of dal/dat and deletion of ActA comprising a nucleic acid molecule encoding an listeriolysin O - prostate specific anigen fusion protein
US9017660B2 (en)	2009-11-11	2015-04-28	Advaxis, Inc.	Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US10016617B2 (en)	2009-11-11	2018-07-10	The Trustees Of The University Of Pennsylvania	Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
KR20180082633A (ko)	2010-05-14	2018-07-18	박스알타 인코퍼레이티드	Ｏｓｐａ 키메라 및 백신에서 그의 용도
AU2011276234B2 (en)	2010-07-06	2016-02-25	Glaxosmithkline Biologicals S.A.	Liposomes with lipids having an advantageous pKa- value for RNA delivery
EP3243526B1 (en)	2010-07-06	2019-11-27	GlaxoSmithKline Biologicals S.A.	Delivery of rna to trigger multiple immune pathways
JP5940064B2 (ja)	2010-07-06	2016-06-29	ノバルティスアーゲー	低用量のｒｎａを用いた大型哺乳動物の免疫化
PT4226941T (pt)	2010-08-31	2024-11-18	Glaxosmithkline Biologicals Sa	Lipossomas peguilados para entrega de arn codificador de imunogénio
EP2621527A4 (en)	2010-10-01	2015-12-09	Univ Pennsylvania	USE OF LISTERIA VACCINE VECTORS TO REVERSE VACCINE IMMUNITY IN PATIENTS WITH PARASITIC INFECTIONS
EP3520813B1 (en)	2010-10-11	2023-04-19	GlaxoSmithKline Biologicals S.A.	Antigen delivery platforms
CA2829960A1 (en)	2011-03-11	2012-09-20	John Rothman	Listeria-based adjuvants
CA2841047A1 (en)	2011-07-06	2013-01-10	Novartis Ag	Immunogenic compositions and uses thereof
EP2729165B1 (en)	2011-07-06	2017-11-08	GlaxoSmithKline Biologicals SA	Immunogenic combination compositions and uses thereof
CN103239734B (zh) *	2012-02-10	2016-02-24	北京艾棣维欣生物技术有限公司	用于预防和/或治疗呼吸道合胞病毒感染的疫苗
AU2013232291B8 (en)	2012-03-12	2016-07-21	Advaxis, Inc.	Suppressor cell function inhibition following listeria vaccine treatment
AU2013293448A1 (en)	2012-07-27	2015-02-05	Baxalta GmbH	Compositions comprising chimeric OspA molecules and methods of use thereof
KR20170052569A (ko)	2014-07-18	2017-05-12	어드박시스, 인크.	전립선암 치료용 pd-1 길항제 및 리스테리아 기반 백신의 병용
MA41644A (fr)	2015-03-03	2018-01-09	Advaxis Inc	Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
WO2016183292A1 (en)	2015-05-14	2016-11-17	Longhorn Vaccines And Diagnostics, Llc	Rapid methods for the extraction of nucleic acids from biological samples
CN110168093B (zh) *	2017-09-12	2023-08-15	中科蓝华(广州)生物医药技术有限公司	一种转染细胞内寄生虫的试剂盒及其应用
JP7284156B2 (ja)	2017-09-19	2023-05-30	アドバクシス，インコーポレイテッド	細菌またはＬｉｓｔｅｒｉａ株の凍結乾燥のための組成物および方法
CA3184128A1 (en)	2020-06-23	2021-12-30	Kathleen Barnes	Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6168804B1 (en) *	1995-06-07	2001-01-02	University Of Alberta	Method for eliciting Th1-specific immune response
JP2000505802A (ja) *	1996-02-12	2000-05-16	コブラセラピューティクスリミテッド	ワクチン接種の新規な方法、ならびにそのための、第１のエピトープをコードする核酸および第２のエピトープを含有するペプチドを含むワクチン
US6093400A (en) *	1996-08-09	2000-07-25	Cel Sci Corporation	Modified HGP-30 peptides, conjugates, compositions and methods of use

1997
- 1997-12-16 GB GBGB9726555.7A patent/GB9726555D0/en not_active Ceased
1998
- 1998-12-11 NZ NZ504936A patent/NZ504936A/xx unknown
- 1998-12-11 KR KR1020007006617A patent/KR20010024731A/ko not_active Application Discontinuation
- 1998-12-11 HU HU0100197A patent/HUP0100197A3/hu unknown
- 1998-12-11 BR BR9814285-2A patent/BR9814285A/pt not_active IP Right Cessation
- 1998-12-11 JP JP2000538712A patent/JP2002508333A/ja active Pending
- 1998-12-11 PL PL98341212A patent/PL341212A1/xx unknown
- 1998-12-11 TR TR2000/01737T patent/TR200001737T2/xx unknown
- 1998-12-11 AU AU19678/99A patent/AU740729B2/en not_active Ceased
- 1998-12-11 EP EP98964509A patent/EP1037662A1/en not_active Withdrawn
- 1998-12-11 US US09/581,368 patent/US6500432B1/en not_active Expired - Fee Related
- 1998-12-11 WO PCT/EP1998/008152 patent/WO1999030733A1/en not_active Application Discontinuation
- 1998-12-11 IL IL13634598A patent/IL136345A0/xx unknown
- 1998-12-11 CA CA002313005A patent/CA2313005A1/en not_active Abandoned
- 1998-12-11 CN CN98813612A patent/CN1284883A/zh active Pending
- 1998-12-15 AR ARP980106358A patent/AR017866A1/es not_active Application Discontinuation
- 1998-12-15 ZA ZA9811501A patent/ZA9811501B/xx unknown
2000
- 2000-06-15 NO NO20003087A patent/NO20003087L/no not_active Application Discontinuation
2002
- 2002-11-12 US US10/292,136 patent/US20030072768A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20003087L (no)	2000-08-08
US20030072768A1 (en)	2003-04-17
BR9814285A (pt)	2000-10-03
HUP0100197A3 (en)	2003-11-28
AU740729B2 (en)	2001-11-15
CA2313005A1 (en)	1999-06-24
NZ504936A (en)	2002-09-27
WO1999030733A1 (en)	1999-06-24
US6500432B1 (en)	2002-12-31
AU1967899A (en)	1999-07-05
CN1284883A (zh)	2001-02-21
HUP0100197A2 (hu)	2001-05-28
KR20010024731A (ko)	2001-03-26
AR017866A1 (es)	2001-10-24
NO20003087D0 (no)	2000-06-15
ZA9811501B (en)	2000-06-15
PL341212A1 (en)	2001-03-26
EP1037662A1 (en)	2000-09-27
JP2002508333A (ja)	2002-03-19
GB9726555D0 (en)	1998-02-11
TR200001737T2 (tr)	2000-12-21

Publication	Publication Date	Title
IL136345A0 (en)	2001-05-20	Method to enhance an immune responce of nucleic acid vaccination
HUP0103214A3 (en)	2003-10-28	Method of dna vaccination
EP0713494A4 (en)	1997-12-17	METHOD FOR SELECTING A NUCLEIC ACID SEQUENCE
EP1027450A4 (en)	2003-03-05	METHOD FOR DNA SHUFFLING
PL338389A1 (en)	2000-10-23	Method of separating acids from sugars
EP0820523A4 (en)	2001-08-16	PRESERVED NUCLEIC ACID SEQUENCES OF YEAST
GB8429297D0 (en)	1984-12-27	Extraction of dna/rna
NZ219421A (en)	1988-11-29	Nucleic acid quantification method & kit
PL338679A1 (en)	2000-11-20	Method of obtaining l-glutamic acid by fermentation
HUP0104881A3 (en)	2003-12-29	Method to produce inactivated w/o emulsion adjuvated vaccines
PL322580A1 (en)	1998-02-02	Method of obtaining nucleic acids
GB8613476D0 (en)	1986-07-09	Method of sequencing nucleic acids
EP0792932A4 (en)	1999-10-20	COPRECIPITATE AND METHOD FOR THE EXTRACTION OF NUCLEIC ACIDS
SG73583A1 (en)	2000-06-20	Method for producing acrylic acid
IL123513A0 (en)	1998-10-30	Identification of bases in nucleic acid sequences
PL339759A1 (en)	2001-01-02	Method of obtaining substituted 4-phenyl-4-cyanohexanic acids
EP0686039A4 (en)	1997-07-02	METHOD FOR IMPROVING THE IMMUNE RESPONSE TO ORAL VACCINES
GB2282138B (en)	1997-09-03	Method of extracting nucleic acids and method of detecting specified nucleic acid sequences
JPS6471500A (en)	1989-03-16	Method for detection of nucleic acid series
IL111857A (en)	1999-09-22	Detection of nucleic acid sequences
GB2333526B (en)	2000-02-23	Method of nucleic acid extraction
AU8258198A (en)	1999-02-22	Separation of nucleic acids by antibodies to halogenated nucleotides
GB9917469D0 (en)	1999-09-29	Extraction of nucleic acids
PL335786A1 (en)	2001-04-09	Method of sequencing nucleic acids
PL334644A1 (en)	2001-01-29	Method of obtaining novel polymethacrylates containing chromaphore-type side groups